Nevro Stock News

REDWOOD CITY, Calif., Dec. 21, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, today announced the settlement of its patent lawsuit with

Federal authorities announced Monday the extradition of a Russian citizen and unveiled charges against four others for their involvement in a hacking scheme to steal and trade on secrets from U.S. pub

Spire Wealth Management lessened its holdings in Nevro Corp. (NYSE:NVRO) by 37.3% in the third quarter, HoldingsChannel.com reports. The firm owned 267 shares of the medical equipment providers stock after selling 159 shares during the period. Spire Wealth Managements holdings in Nevro were worth $31,000 as of its most recent filing with the Securities and []

REDWOOD CITY, Calif., Dec. 20, 2021 /PRNewswire/ -- In a release issued under the same headline on December 10, 2021 by Nevro Corp. (NYSE: NVRO), please note that the presentation time has been updat

Shares of Nevro Corp. (NYSE:NVRO) have been assigned a consensus recommendation of Hold from the sixteen research firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and five have issued a buy rating on the company. The average []

New Jersey, United States,- Verified Market Research has recently published a research report titled, Sacral Nerve Stimulation Market Size, and Forecast 2021-2028, Breakdown Data by Manufacturers, Key Regions, Types and Application. Primary and secondary research methodologies have been used to

Nevro Corp. (NYSE:NVRO)s traded shares stood at 0.52 million during the last session, with the companys beta value hitting 1.06. At the close of trading, the stocks price was $86.60, to imply a decrease of -3.26% or -$2.92 in intraday trading. The NVRO shares 52-week high remains $188.14, putting it -117.25% down since that peak After Plunging -0.80% During Past Week, Is Nevro Corp. (NYSE: NVRO) Still A Buy? Read More »

Equities analysts expect Nevro Corp. (NYSE:NVRO) to announce earnings of ($0.85) per share for the current quarter, Zacks reports. Six analysts have provided estimates for Nevros earnings. The highest EPS estimate is ($0.74) and the lowest is ($0.93). Nevro posted earnings of ($0.21) per share in the same quarter last year, which indicates a negative []

Nisa Investment Advisors LLC boosted its position in shares of Nevro Corp. (NYSE:NVRO) by 50.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,350 shares of the medical equipment providers stock after purchasing an additional 450 shares during the quarter. Nisa []

REDWOOD CITY, Calif., Dec. 10, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain,

Equities analysts predict that Nevro Corp. (NYSE:NVRO) will announce $96.54 million in sales for the current quarter, according to Zacks Investment Research. Six analysts have made estimates for Nevros earnings. The lowest sales estimate is $95.88 million and the highest is $97.47 million. Nevro posted sales of $109.73 million during the same quarter last year, []

Global Spinal Cord Stimulation Devices Market Insights and Forecast to 2027 The Spinal Cord Stimulation Devices Market Report 2021-2027 provides global market size, regional and national level market size, market segment growth, market share, competitive landscape, sales analysis, influence of domestic

Equities research analysts expect that Nevro Corp. (NYSE:NVRO) will announce ($0.85) earnings per share for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Nevros earnings. The highest EPS estimate is ($0.74) and the lowest is ($0.93). Nevro posted earnings of ($0.21) per share during the same quarter last year, which []

Nevro Corp. (NYSE:NVRO) concluded the trading at $87.30 on Friday, December 03 with a fall of -4.40% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $91.32 and 5Y monthly beta was reading 0.99 with its price kept floating in the range Nevro Corp. (NVRO) Is Waiting On The Launchpad To Make A Splash. Read More »